The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD).

Details On Trials

Compass Pathways plc (NASDAQ: CMPS) will initiate the UK arm of its Phase 3 program on psilocybin therapy COMP360 for Treatment-Resistant Depression (TRD).

The ongoing program is reportedly the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. It consists of two pivotal trials, COMP 005 and COMP 006, each with an integrated long-term outcomes component.

Following the MHRA approval of the study, the multiple UK sites to participate in part of the company’s pivotal Phase 3 program include Compass’ newly-opened Centre for Mental Health Research and Innovation in London, where COMP 006 (assessing 25mg, 10mg and 1mg of COMP360) will take place.

Developed in partnership with South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology & Neuroscience at King’s …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.